Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
Status:
Completed
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the
safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the
treatment of NSCLC and to select a recommended phase 2 dose (RP2D).